UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis

Journal of hepatology, 2020-06, Vol.72 (6), p.1112-1121

2020

Link zum Volltext

Verfügbarkeit prüfen

Development and Clinical Validation of a Pangenotypic PCR-Based Assay for the Detection and Quantification of Hepatitis E Virus ( Orthohepevirus A Genus)

Journal of clinical microbiology, 2021-01, Vol.59 (2)

2021

Link zum Volltext

Verfügbarkeit prüfen

Pangenotypic direct‐acting antiviral agents for mixed genotype hepatitis C infection: A real‐world effectiveness analysis

Journal of gastroenterology and hepatology, 2021-10, Vol.36 (10), p.2911-2916

2021

Link zum Volltext

Verfügbarkeit prüfen

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

Journal of hepatology, 2018-08, Vol.69 (2), p.293-300

2018

Link zum Volltext

Verfügbarkeit prüfen

Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis

Journal of hepatology, 2017-08, Vol.67 (2), p.263-271

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis

Antimicrobial agents and chemotherapy, 2019-12, Vol.63 (12)

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Clinical gastroenterology and hepatology, 2018-03, Vol.16 (3), p.417-426

2018

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy

Hepatology international, 2017-03, Vol.11 (2), p.161-170

2017

Link zum Volltext

Verfügbarkeit prüfen

Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients

Expert review of anti-infective therapy, 2024-05, p.1-6

2024

Link zum Volltext

Verfügbarkeit prüfen

The Efficacy of Generic Daclatasvir-Sofosbuvir as Pan-Genotypic Regiment for Hepatitis C Virus (HCV) Infected Patients in Bandung Indonesia

The Indonesian journal of gastroenterology, hepatology, and digestive endoscopy (Jakarta), 2020-07, Vol.21 (1), p.7-11

2020

Link zum Volltext

Verfügbarkeit prüfen

Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis

EClinicalMedicine, 2020-01, Vol.18, p.100237-100237, Article 100237

2020

Link zum Volltext

Verfügbarkeit prüfen

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection

Clinical gastroenterology and hepatology, 2020-10, Vol.18 (11), p.2544-2553.e6

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

Liver international, 2020-05, Vol.40 (5), p.1032-1041

2020

Link zum Volltext

Verfügbarkeit prüfen

Single-Ascending-Dose, Food-Effect, and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Pangenotypic Anti-Hepatitis C Virus Drug Holybuvir in Healthy Chinese Subjects

Antimicrobial agents and chemotherapy, 2023-03, Vol.67 (3), p.e0129522-e0129522

2023

Link zum Volltext

Verfügbarkeit prüfen

Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?

Antiviral research, 2023-12, Vol.220, p.105742-105742, Article 105742

2023

Link zum Volltext

Verfügbarkeit prüfen

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

World journal of gastroenterology : WJG, 2023-04, Vol.29 (13), p.2015-2033

2023

Link zum Volltext

Verfügbarkeit prüfen

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients

World journal of gastroenterology : WJG, 2022-12, Vol.28 (45), p.6380-6396

2022

Link zum Volltext

Verfügbarkeit prüfen

Genotype 3-hepatitis C virus' last line of defense

World journal of gastroenterology : WJG, 2021-03, Vol.27 (11), p.1006-1021

Zarębska-Michaluk, Dorota

2021

Link zum Volltext

Verfügbarkeit prüfen

Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single‐arm, open‐label, phase 3 trial

Liver international, 2020-11, Vol.40 (11), p.2685-2693

2020

Link zum Volltext

Verfügbarkeit prüfen

High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar

Journal of viral hepatitis, 2019-10, Vol.26 (10), p.1186-1199

2019

Link zum Volltext

Verfügbarkeit prüfen

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals

Clinical and experimental hepatology, 2023-01, Vol.9 (3), p.193-201

2023

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir

Journal of clinical microbiology, 2019-04, Vol.57 (4)

2019

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China

Journal of gastroenterology and hepatology, 2018-06, Vol.33 (6), p.1168-1176

2018

Link zum Volltext

Verfügbarkeit prüfen

Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection

Reviews on recent clinical trials, 2019-01, Vol.14 (3), p.173

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(48)
Science & Technology
(48)
Pangenotypic
(39)
Hepatitis C
(31)
Humans
(30)
Gastroenterology & Hepatology
(25)
Hepatitis C, Chronic - Drug Therapy
(24)
Hepatitis C Virus
(22)
Hepacivirus - Genetics
(21)
Direct-Acting Antivirals
(19)
Genotype
(19)
Antiviral Agents - Therapeutic Use
(17)
Liver Cirrhosis
(17)
Male
(14)
Sustained Virologic Response
(14)
Hepatitis C - Drug Therapy
(13)
Interferon
(13)
Cirrhosis
(12)
Genotypes
(12)
Patients
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis

Development and Clinical Validation of a Pangenotypic PCR-Based Assay for the Detection and Quantification of Hepatitis E Virus ( Orthohepevirus A Genus)

Pangenotypic direct‐acting antiviral agents for mixed genotype hepatitis C infection: A real‐world effectiveness analysis

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial

Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients

The Efficacy of Generic Daclatasvir-Sofosbuvir as Pan-Genotypic Regiment for Hepatitis C Virus (HCV) Infected Patients in Bandung Indonesia

Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

Single-Ascending-Dose, Food-Effect, and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Pangenotypic Anti-Hepatitis C Virus Drug Holybuvir in Healthy Chinese Subjects

Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients

Genotype 3-hepatitis C virus' last line of defense

Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single‐arm, open‐label, phase 3 trial

High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals

In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir

Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China

Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection

Suchergebnisse filtern